Skip to main content
DNA Labs India

Oncomine Acute Myeloid Leukaemia (AML) Panel Test

DNA Labs India | ISO 9001:2015 Certified

Oncomine Acute Myeloid Leukaemia (AML) Panel Test

Short Name: Oncomine AML Panel

Also known as: Oncomine AML Panel, AML Comprehensive Genomic Panel, Acute Myeloid Leukemia NGS Panel, AML Mutation Panel

Oncomine Acute Myeloid Leukaemia (AML) Panel Test test available at DNA Labs India for ₹40,950. Uses Next-Generation Sequencing (NGS) on Whole Blood or Bone Marrow samples. Results in Reports are generated by the 15th or 30th of the same month, depending on whether the sample was received by the 1st or 16th of the month, respectively. Reports will be available via the online portal, email, and WhatsApp.. Free home collection in 300+ cities across India.

Next-Generation Sequencing (NGS)All Ages🏠 Home Collection

✍️ Written By

🩺 Medically Reviewed By

Dr SULOCHANA HEMCHANDRA HOLLA

Dr SULOCHANA HEMCHANDRA HOLLA

Consultant Medical Geneticist · Reg: 8532

Last reviewed: September 7, 2026

Overview

The Oncomine AML Panel Test is used to identify genetic mutations and fusion genes in patients with suspected or confirmed Acute Myeloid Leukaemia. It aids in molecular subtyping, prognostic stratification, and selection of targeted therapies including FLT3 inhibitors, IDH inhibitors, and other precision medicine approaches. This panel detects mutations in genes such as ABL1, ASXL1, BCOR, BAALC, CBL, CEBPA, DNMT3A, EZH2, ETV6, FLT3, GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MYD88, MYC, MECOM, NRAS, NPM1, NF1, PHF6, PRPF8, PTPN11, RUNX1, SF3B1, SRSF2, SMC1A, SH2B3, STAG2, TET2, TP53, U2AF1, WT1, and ZRSR2, as well as fusion genes involving ABL1, BCL2, CCND1, CREBBP, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A, MECOM, MLL, MYH11, MLLT3, MLLT10, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, and TCF3.

Test Code
1358
CPT Code
81450
ICD Code
C92.0
Price
₹40,950
Sample Type
Whole Blood or Bone Marrow
Result Time
Reports are generated by the 15th or 30th of the same month, depending on whether the sample was received by the 1st or 16th of the month, respectively. Reports will be available via the online portal, email, and WhatsApp.
Fasting Required
No
Method
Next-Generation Sequencing (NGS)
Step 1

Sample Collection

Duly filled NGS Test Requisition Form (Form 40) is mandatory before sample collection. No fasting is required. Inform your doctor about any recent blood transfusions, medications, or ongoing treatments. Ensure the patient's demographic details and clinical history are accurately provided on the requisition form.

Method: Venipuncture / Bone Marrow Aspiration

Step 2

Laboratory Analysis

Collect 3 mL (minimum 2 mL) of whole blood by venipuncture into a Lavender top (EDTA) tube. For bone marrow samples, collect into the same EDTA tube type. Label the sample clearly with patient name, date of birth, and sample ID. Ensure proper mixing to prevent clotting.

Step 3

Report Delivery

Ship the sample refrigerated (2–8°C). Do NOT freeze the sample. The sample must reach the laboratory within 72 hours of collection when refrigerated. At room temperature, sample stability is limited to 6 hours. Ensure the NGS Test Requisition Form (Form 40) accompanies the sample.

Timeline: Reports are generated by the 15th or 30th of the same month, depending on whether the sample was received by the 1st or 16th of the month, respectively. Reports will be available via the online portal, email, and WhatsApp.

Patient Instructions

1
Before the Test:No special preparation such as fasting is required. Ensure the NGS Test Requisition Form (Form 40) is completely and accurately filled out. Inform your doctor about any recent blood transfusions (within 4 weeks), current medications, or ongoing chemotherapy. Carry a valid photo ID and doctor's prescription at the time of sample collection.
2
During the Test:A blood sample (3 mL) will be drawn from a vein in your arm into an EDTA tube. If a bone marrow sample is required, a bone marrow aspiration will be performed by a trained specialist under local anaesthesia. The procedure typically takes 10–15 minutes for blood collection or 20–30 minutes for bone marrow aspiration.
3
After the Test:After blood collection, standard post-venipuncture care applies—press the puncture site for a few minutes. If a bone marrow biopsy was performed, the site will be bandaged and you may experience mild soreness for 1–2 days. No specific activity restrictions are recommended. Your sample will be transported to our NGS laboratory for processing.

About This Test

Who Should Get This Test

The Oncomine AML Panel Test is used to identify genetic mutations and fusion genes in patients with suspected or confirmed Acute Myeloid Leukaemia. It aids in molecular subtyping, prognostic stratification, and selection of targeted therapies including FLT3 inhibitors, IDH inhibitors, and other precision medicine approaches. This panel detects mutations in genes such as ABL1, ASXL1, BCOR, BAALC, CBL, CEBPA, DNMT3A, EZH2, ETV6, FLT3, GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MYD88, MYC, MECOM, NRAS, NPM1, NF1, PHF6, PRPF8, PTPN11, RUNX1, SF3B1, SRSF2, SMC1A, SH2B3, STAG2, TET2, TP53, U2AF1, WT1, and ZRSR2, as well as fusion genes involving ABL1, BCL2, CCND1, CREBBP, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A, MECOM, MLL, MYH11, MLLT3, MLLT10, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, and TCF3.

How to Prepare

  • Collect 3 mL (2 mL min.) whole blood by venipuncture into a Lavender top (EDTA) tube
  • Alternatively, bone marrow aspirate may be collected in an EDTA tube
  • Do NOT freeze the sample at any point
  • Ship refrigerated (2–8°C) to the laboratory
  • Duly filled NGS Test Requisition Form (Form 40) is mandatory
  • Label the sample tube clearly with patient details and sample ID

Doctor's Notes

Reviewed by — MBBS, MD (Medical Genetics) · Reg. No. 8532

"The Oncomine AML Panel is a critical tool in modern oncology practice. Identifying actionable mutations such as FLT3, IDH1/IDH2, and NPM1 allows oncologists to tailor therapy with targeted agents, improving response rates and potentially overall survival. This panel also identifies fusion genes that may guide the use of specific kinase inhibitors or predict response to conventional chemotherapy. I recommend this test for all newly diagnosed AML patients and those with relapsed or refractory disease to inform evidence-based treatment decisions."

Last medically reviewed: September 7, 2026

Test Parameters & Specifications

Sample TypeWhole Blood or Bone Marrow
Sample Volume3 mL (2 mL min.) whole Blood OR Bone Marrow
Container1 Lavender top (EDTA) tube
Collection MethodVenipuncture / Bone Marrow Aspiration

Sample Stability

Room Temperature (15–25°C)
Refrigerated (2–8°C)
Frozen (−20°C or below)
Sample Rejection Criteria:
  • Sample received without the NGS Test Requisition Form (Form 40)
  • Haemolysed, clotted, or inadequately labelled samples
  • Sample volume less than the minimum required (2 mL)
  • Sample received frozen or thawed after freezing
  • Sample received at room temperature beyond 6 hours of collection
  • Sample received refrigerated beyond 72 hours of collection
  • Samples collected in non-EDTA anticoagulants (e.g., heparin, citrate)

Understanding Your Results

The Oncomine AML Panel Test report provides a comprehensive summary of detected somatic mutations and fusion genes, including variant allele frequency, functional consequence, clinical significance, and available therapeutic implications. Mutations are classified based on their known pathogenicity and relevance to AML biology. Results should be interpreted by a qualified haematologist or oncologist in the context of the patient's clinical presentation, morphological findings, flow cytometry results, and conventional cytogenetics.
📊

Associated with adverse prognosis in AML. Consider FLT3 inhibitors (e.g., midostaurin, gilteritinib) as part of treatment strategy.

📊

Generally associated with favourable prognosis. May guide treatment intensity decisions.

📊

Targetable with IDH inhibitors (ivosidenib for IDH1, enasidenib for IDH2). Consider as a therapeutic option.

📊

Associated with favourable prognosis, particularly in the absence of other adverse-risk mutations.

📊

Associated with very poor prognosis and resistance to conventional chemotherapy. Consider allogeneic stem cell transplantation or clinical trials.

📊

Associated with adverse prognosis. May influence decisions regarding allogeneic stem cell transplantation in first remission.

📊

Defines specific AML subtypes with diagnostic and therapeutic significance. Fusion-specific targeted therapy may be indicated.

📊

Does not completely exclude AML. Correlate with clinical presentation, morphological, immunophenotypic, and cytogenetic findings. Repeat testing or alternative assays may be considered if clinical suspicion remains high.

⚠️ When to Consult a Doctor:

Consult your haematologist or oncologist if you experience persistent fatigue, unexplained fever, frequent infections, easy bruising or bleeding, shortness of breath, or unexplained weight loss. If your CBC shows unexplained cytopenias or abnormal white cell counts, seek specialist evaluation promptly. If this test has been ordered, discuss the results with your treating oncologist, who will integrate molecular findings with your overall clinical picture to plan appropriate treatment.

Limitations

  • ⚠This panel detects known mutations and fusion genes included in the assay design; novel or rare variants outside the panel may not be identified
  • ⚠Copy number variations (CNVs) and large structural rearrangements beyond the fusion gene targets may not be fully characterised
  • ⚠Results should always be interpreted in conjunction with clinical findings, morphological evaluation, flow cytometry, and cytogenetic analysis
  • ⚠The test does not replace conventional karyotyping or FISH studies
  • ⚠Variant allele frequency (VAF) detection limit is approximately 5%; variants below this threshold may not be reliably detected

Risks & Considerations

  • ●For blood collection: Minimal risk—may include slight bruising or discomfort at the venipuncture site
  • ●For bone marrow aspiration: Mild to moderate pain at the aspiration site, minor bleeding or infection risk (rare)
  • ●No radiation exposure is involved as this is a molecular/genetic test

Interfering Factors

  • ●Degraded or insufficient DNA quality may affect sequencing accuracy
  • ●Recent blood transfusions within the past 4 weeks may dilute tumour DNA and produce false-negative results
  • ●Sample haemolysis or clotting may compromise DNA extraction
  • ●Use of anticoagulants other than EDTA may interfere with sample integrity
  • ●Low tumour cellularity in the bone marrow aspirate may reduce sensitivity for detecting somatic variants

Compare With Similar Tests

TestOncomine Acute Myeloid Leukaemia (AML) Panel TestOncomine Myeloid PanelFLT3 Mutation AnalysisNPM1 Mutation AnalysisBCR-ABL1 Qualitative (RT-PCR)
ComparisonOncomine Acute Myeloid Leukaemia (AML) Panel Test

Frequently Asked Questions

What is the Oncomine AML Panel Test?
The Oncomine AML Panel Test is a comprehensive next-generation sequencing (NGS) genetic test that detects somatic mutations and fusion genes in over 35 genes commonly associated with Acute Myeloid Leukaemia (AML). It helps in molecular diagnosis, prognostic stratification, and selection of targeted therapies.
What sample is required for this test?
The test requires 3 mL (minimum 2 mL) of whole blood collected in a Lavender top (EDTA) tube, or a bone marrow aspirate in an EDTA tube. The sample should be shipped refrigerated and must not be frozen.
Is fasting required before sample collection?
No, fasting is not required for the Oncomine AML Panel Test. You can eat and drink normally before sample collection.
How much does the Oncomine AML Panel Test cost at DNA Labs India?
The cost of the Oncomine AML Panel Test at DNA Labs India is INR 40,950. This includes genetic testing, variant interpretation, a detailed clinical report, and free home sample collection across India.
How long does it take to get the results?
Samples submitted by the 1st of the month will have reports by the 15th, and samples submitted by the 16th will have reports by the 30th of the same month. Reports are delivered via online portal, email, and WhatsApp.
Who should get the Oncomine AML Panel Test?
This test is recommended for patients newly diagnosed with AML, those with relapsed or refractory AML, patients with abnormal CBC results suggestive of myeloid malignancy, and anyone being evaluated for targeted therapy such as FLT3 or IDH inhibitors.
What genes and mutations does this panel test for?
The panel tests for mutations in 35+ genes including FLT3, NPM1, IDH1, IDH2, CEBPA, TP53, RUNX1, DNMT3A, ASXL1, TET2, and many more. It also detects 24 clinically relevant fusion genes involving genes such as KMT2A, RUNX1, RARA, PDGFRA, and FGFR1.
How is this test different from a bone marrow biopsy?
A bone marrow biopsy examines the morphology and cellular composition of the bone marrow, while the Oncomine AML Panel analyses the DNA of cancer cells at the molecular level to identify specific genetic mutations and fusion genes. Both tests are complementary and often performed together for comprehensive AML evaluation.
Can this test help in choosing targeted therapy for AML?
Yes. The Oncomine AML Panel identifies actionable mutations such as FLT3, IDH1, and IDH2, for which targeted FDA/DCGI-approved inhibitors are available. This information helps oncologists personalise treatment and potentially improve patient outcomes.
Is the Oncomine AML Panel Test covered by insurance?
Coverage depends on your specific insurance policy and scheme. Government schemes such as PMJAY, CGHS, ECHS, and ESIC may have limited coverage for advanced molecular tests. We recommend contacting your insurance provider with the test details and CPT code for pre-authorization. DNA Labs India can provide a detailed invoice to support your claim.
Is home sample collection available for this test?
Yes, DNA Labs India offers free home sample collection for the Oncomine AML Panel Test across India. You can book online and a trained phlebotomist will visit your location. This service is available in all major cities and many tier-2 and tier-3 cities nationwide.
What happens if no mutations are detected?
If no mutations or fusion genes are detected, it does not completely rule out AML. The result should be correlated with clinical presentation, morphological findings, flow cytometry, and cytogenetic analysis. Your doctor may recommend additional testing or alternative diagnostic approaches if clinical suspicion remains.
Worried about the process? Our certified phlebotomists collect thousands of samples every month across India. The process takes under 5 minutes and is virtually painless. Questions? Message us on WhatsApp — we're here 7 days a week.

Related Tests

B-Cell Rearrangement Detection Test

₹22,000

Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test

₹20,000

Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test

₹6,000

OncoPro NCCN Lung Cancer Panel with PD-L1 Test

₹140,400

Acute Myeloid Leukemia (AML) Cytogenetics Panel Test

₹23,000

AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test

₹6,000
For Hospitals & Clinics

Reference Laboratory Services

We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.

LIMS Integration

Your Data Privacy

Your medical data is protected under Indian law.

✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.

✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.

Book Your Test

Enter your details and we'll connect you within 15 minutes.

🧬

Quick Connect

Enter your mobile number and we’ll connect you with the team.

+91

✅ Connecting you now...

🔒 Your number is used to respond to this request.